Objective: After the initial report of a CHCHD10 mutation in mitochondrial disease with features resembling amyotrophic lateral sclerosis (ALS), CHCHD10 mutations have been considered to be a frequent cause for ALS. However, the exact pathogenicity and clinical significance of these mutations remain unclear. Here, we aimed to determine the role of CHCHD10 mutations in ALS. Methods: We analyzed 4,365 whole genome sequenced ALS patients and 1,832 controls from 7 different countries and examined all nonsynonymous single nucleotide variants in CHCHD10. These were tested for association with ALS, independently and in aggregate using several genetic burden tests (including sequence kernel association test [SKAT], optimal unified test [SKAT-O], and Firth logistic regression). Results: We identified 3 new variants in cases, but only 1 was ALS-specific. Also, 1 control-specific mutation was identified. There was no increased burden of rare coding mutations among ALS patients compared to controls (p = 0.86, p = 0.86, and p = 0.88 for SKAT, SKAT-O, and Firth, respectively). The few carriers with potential pathogenic CHCHD10 mutations exhibited a slowly progressive ALS-like phenotype with atypical features such as myopathy and deafness. Interpretation: CHCHD10 mutations seem to be a far less prevalent cause of pure ALS than previously suggested, and instead appear related to more complex phenotypes. There appears to be insufficient evidence for the pathogenicity of most previously reported variants in pure ALS. This study shows that routine testing for CHCHD10 mutations in pure ALS is not recommended and illustrates the importance of sufficient genetic and functional evidence in establishing pathogenicity of genetic variants. ANN NEUROL 2018;84:110-116 A myotrophic lateral sclerosis (ALS) is a rapidly progressive neurological disease characterized by the degeneration of both upper and lower motor neurons, leading to progressive muscle weakness and respiratory failure.
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Using next generation sequencing, mutations in several genes have been reported, especially in the minority of cases with a positive family history of ALS. 2 These discoveries have not only led to increased understanding of the pathophysiology of ALS and the possible development of specific therapeutic agents, but also play an important role in genetic counseling. CHCHD10 was proposed as a new candidate gene for ALS, after a novel p.Ser59Leu mutation in CHCHD10 was described as cosegregating with a complex variable phenotype, including cognitive decline resembling frontotemporal dementia (FTD), cerebellar ataxia, myopathy, sensorineural deafness, and an ALS-like motor neuron disease. 3 Although subsequent screening in different populations has led to the description of >20 mutations in CHCHD10 (most of which are located in exon 2) [4] [5] [6] [7] in ALS and other neurodegenerative diseases, our certainty in the causality of these variants for ALS remains an open question. 8, 9 Typically, to establish the causality of the identified CHCHD10 variants, investigators used predictive software for individual mutations to indicate a deleterious effect and (virtual) absence in public databases. However, it is widely accepted that these criteria alone are insufficient proof of causality for low-frequency variants, 8 especially if those variants were identified only once in a single index case. Consequently, these lenient criteria for claiming causality between a variant and disease might lead to falseAdditional supporting information can be found in the online version of this article.
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positive reports due to inadequate coverage in exomecaptured data, geographically specific genetic variation, and underpowered studies. 10 To determine the veracity of claims that CHCHD10 variants are causal in ALS and valid to use in the clinic, we have set out to investigate the genetic contribution of CHCHD10 variants in a large international cohort of whole genome sequenced ALS patients and controls.
Subjects and Methods

Sample Collection
DNA was isolated from whole blood samples collected from 4,853 ALS patients from 7 different populations (Belgium, Ireland, the Netherlands, the United Kingdom, the United States of America, Spain, and Turkey) and 1,991 controls matched for age, geographical location, and sex. All patients and control subjects provided written informed consent, and the relevant institutional review boards approved this study.
Sequencing and Analysis
DNA samples were sequenced using polymerase chain reactionfree library preparation and paired-end sequencing on the HiSeq 2000 (100bp) and HiSeq X platform (150bp; Illumina, San Diego, CA). Reads were aligned to the hg19 human genome build using the Isaac alignment software, and the Isaac variant caller was used to call and filter single nucleotide variants using standard quality control (QC) parameters. 13 Additional QC removed duplicated or poorly called individuals (genotype missingness > 5%, transition/transversion (Ti/Tv) ratio > 2.092, heterozygous/ homozygous ratio > 3.1) and genomic sites (high or low depth of coverage, aggregated passing rate < 0.7 across the sample, missingness > 5%, Hardy-Weinberg equilibrium p < 1 × 10
−6
). We also removed all closely related (kinship coefficient > 0.0625) and sexcheck failing samples based on comparison of phenotype and sequencing data.
14 The genomic region of CHCHD10 (NCBI Reference Sequence NG_034223.1) was isolated from the Variant Call Format files (VCFs), and variants were annotated using Variant Effect Predictor. 15 
Burden Testing
Gene regions were isolated based on their canonical transcripts in the Ensembl database (http://www.ensembl.org). Within these regions, single nucleotide variants (SNVs) that were annotated as missense or loss-of-function mutations with a minor allele frequency < 1% in the control population and public databases were selected for burden testing. Burden testing on cases and controls was performed using bidirectional sequence kernel association test (SKAT) together with SKAT-O to account for a unidirectional effect (which is more likely in the case of mainly damaging variants) and Firth corrected logistic regression. [16] [17] [18] Association tests were corrected for population stratification using the first 10 principal components. Additionally, 100,000 permutations were performed with SKAT-O and Firth logistic regression to obtain the empirical p values. Statistical analyses were carried out using R software (http://www. r-project.org).
Results
To investigate variants in CHCHD10, we analyzed all rare, nonsynonymous SNVs in the whole genome sequencing data of 4,365 ALS (±FTD) samples together with 1,832 unaffected controls. We identified 7 SNVs in ALS cases, 3 of which were not previously reported (Table 1) . Screening of controls revealed that only 3 of these 7 variants were ALS-specific, as the other 4 variants were also found in controls. Additionally, 1 controlspecific SNV was identified.
No Increased Burden of Rare Variants
None of the different association tests showed a significant increased burden of rare nonsynonymous variants in CHCHD10 among ALS patients (SKAT: p = 0.86; SKAT-O: p = 0.86; Firth: p = 0.88; Table 2 ). As a positive control, we tested 3 other genes (SOD1, FUS, and TARDBP), which are known to harbor rare pathogenic SNVs in ALS. 19 These genes did yield significant association statistics in both SKAT-O and Firth, indicating a unilateral effect (see Table 2 ).
Additional Clinical Information on Carriers
Only 3 rare missense mutations in CHCHD10 were specific to ALS cases (Supplementary Table 1 ). The previously unreported p.Arg11Gly mutation was identified in a single female ALS case from the United States without cognitive involvement and a negative family history for ALS or dementia. We identified 3 cases with the previously reported p.Arg15Leu variant: 1 Dutch and 2 American cases, 1 of which was already included in the previous study by Johnson et al (ND11809). 5 Although both
American cases had a positive family history, the additional Dutch ALS patient did not have a family history of ALS or dementia. Similar to previously described carriers, the clinical phenotype in this patient was characterized by very slow progression with both upper and lower motor neuron involvement, a long diagnostic delay of 2 years, and a disease duration of >8 years after onset. 5, 6, 20 Interestingly, besides motor neuron disease, this patient presented with an atypical phenotype including deafness, weakness of the proximal upper extremities, and reduced tendon reflexes. Unfortunately, no muscle biopsies were performed to detect myopathy. The third case-specific mutation (p.Pro80Leu), previously reported in an Italian ALS patient with an abnormal muscle biopsy (cytochrome c oxidase [COX] deficiency), was found in a Belgian ALS patient. 7 This patient also presented with an atypical myopathylike clinical phenotype with proximal lower limb weakness and high serum creatine kinase levels (up to 1,800U/l). The clinical features at the time of presentation prompted the neurologist to request a muscle biopsy, which showed neurogenic atrophy, but without histochemical analysis for COX.
Discussion
CHCHD10 was proposed as a new candidate gene for ALS following the initial report of a p.Ser59Leu variant, which was detected in a family with a complex phenotype including ataxia, myopathy, dementia, and a progressive motor neuron disease resembling ALS. 3 Subsequently, several studies screened for CHCHD10 mutations in ALS patients and healthy controls and claimed pathogenicity for multiple rare missense variants. [4] [5] [6] In this study, we used whole genome sequencing data on a large international cohort of ALS patients to investigate the frequency of CHCHD10 variants and evaluated the genetic evidence for their pathogenicity. In our cohort of 4,365 ALS patients and 1,832 controls, we only detected 3 rare, case-specific, missense variants, 2 of which have been previously reported. The only remaining novel ALS-specific variant, a heterozygous c.31C>G variant resulting in a p.Arg11Gly amino acid change, was found in a single ALS case and is therefore of unknown significance. Furthermore, we also identified a rare missense variant (p.Ala72Val) in a single control sample, indicating that unique coding variants can be found in controls as well. Together with our data, there are now 13 reported rare nonsynonymous variants in CHCHD10 in cases diagnosed with pure ALS, most of which are concentrated in exon 2 (Fig 1) . Missense mutations in exon 2 were also detected in other neurodegenerative diseases, some of which are closely related to ALS. Although this might hint toward pleiotropy, it is important to realize that most reported variants were unique to a single case or family and that this exon is only moderately covered in whole exome sequencing-based public databases such as ExAC, making it prone to false-positive reports. For instance, at the p.Arg15Leu variant site, chr22:24109778, the fraction of individuals in ExAC with coverage of 20× or higher was only 0.0003. 10 To interpret the collection of rare variants in cases and/or controls, we tested whether there is an increased burden of rare nonsynonymous variants in CHCHD10 among ALS patients. The results of the association tests show no significant association between rare coding variants in CHCHD10 and ALS, whereas rare variants in FUS, TARDBP, and SOD1 did show a significant association of nonsynonymous variants in ALS using both SKAT-O and Firth corrected association tests. SKAT p values were not significant, which was expected, as variants in these genes are known to be damaging, not protective. Although mutations in these genes are considered rare but not uncommon in sporadic ALS, the difference in association signal does not exclude pathogenicity of CHCHD10 variants in ALS; it does, however, indicate a very low prevalence.
In the absence of linkage or a statistically significant burden test, all variants that are solely observed in a single index case do not meet criteria for pathogenicity. 8 Only variants that occur in multiple unrelated cases (and absent or extremely rare in controls) are potentially more interesting. Together with previous reports, only 6 CHCHD10 variants have met this criterion ( Table 3) . Some of these variants are already listed as (possibly) pathogenic in public databases such as ClinVar despite other criteria for establishing pathogenicity often not being investigated.
So far, the most convincing evidence for CHCHD10 pathogenicity was provided for the p.Ser59Leu variant, using both clinical and genetic data on multiple affected and unaffected family members. The clinical phenotype described in these carriers, however, is not pure ALS and includes atypical features such as deafness, myopathy, cerebellar ataxia, and Parkinsonism. 3 With our focus on typical ALS, we will critically appraise the genetic evidence for the 5 other reported variants. Similar to previous observations, the most frequent rare nonsynonymous SNV in our dataset was the heterozygous p.Pro34Ser, which was present in 37 cases (0.85%) as well as 15 control samples (0.82%; corrected χ Overview of total number of alleles and variant alleles, evidence of segregation in pedigrees, and reported clinical significance in ClinVar database of variants that were previously and currently reported in multiple (>1) seemingly unrelated ALS or FTD patients. Alleles that were present in affected or unaffected family members were excluded. No overlap indicates the minimum number of alleles that were screened in nonoverlapping cohorts (after removal of UK, US, and Spanish cohorts). ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia. a In a pedigree with FTD.
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b Allele counts were not provided in all reports. 27 pathogenicity of this variant in pure ALS ± FTD, our data add to the increasing evidence that the p.Pro34Ser mutation in CHCHD10 is probably not pathogenic. [21] [22] [23] [24] Recent in vitro studies still support p.Pro34Ser pathogenicity, as similar cellular pathology between CHCHD10
S59L
and CHCHD10 P34S mutant cell lines was shown. 25 Despite the in vitro findings, that the p.Pro34Ser variant is as common in ALS patients as in the general population indicates that an apparently abnormal phenotype in transfected cell lines alone does not justify classifying the p.Pro34Ser variant as an ALS-causing mutation and indicates the substantial limitation of these models to represent human ALS pathology. Previous screening of a subset of sporadic ALS patients with COX-deficient muscle biopsies led to the discovery of a c.244C>T substitution (p.Pro80Leu) in exon 2, which was subsequently reported in 2 sporadic ALS cases and 1 familial ALS case in Italy and Canada. 7, 26 We have identified an additional sporadic case in our Belgian cohort with a similar atypical clinical phenotype. However, the allele frequency of this variant in ALS cases after exclusion of possibly overlapping cohorts (5/12,700 = 0.0004) is almost identical to the general population in the ExAC database (32/92,470 = 0.0003, corrected χ 2 [1] = 0.00, p = 0.99). Moreover, the frequency in the ExAC database might even be an underestimation, as exon 2 is only moderately represented (see Fig 1) . The fourth and fifth variants, which were identified in multiple ALS cases, are the p.Pro96Thr and p. Tyr135His mutations. These variants are located in exon 3 and, similar to p.Pro80Leu, pathogenicity is unlikely due to similar allele frequencies in control samples. 22, [27] [28] [29] Notably, the p.Pro96Thr is the only variant that was found to be homozygous in 3 of 5 cases. Given its high frequency in the African population in ExAC (692/2,704 = 0.2559), however, a pathogenic recessive nature of this mutation seems highly unlikely.
The last variant, c.44G>T (p.Arg15Leu), was previously detected in 6 families with ALS and 1 sporadic ALS case. 5, 6, 20, 30 This variant is probably of the greatest interest in ALS, as it was identified in multiple cohorts, segregated with disease in familial cases (although there were 3 unaffected carriers in 1 family, reflecting incomplete penetrance), and was absent in any of the screened controls. 6 Here, we report 2 new carriers: 1 in the Dutch cohort and 1 in the US cohort (the other US carrier has already been reported). Although limited, the available clinical data for these patients are similar to previously reported carriers (predominant lower motor neuron signs and slow disease progression), with some atypical features in 1 patient (bilateral hearing loss and proximal onset), supporting an ALSlike clinical phenotype. 6, 20 However, the percentage of ALS cases associated with this variant is 0.1% (9/6,797 nonoverlapping cases), making it a possibly pathogenic but very rare CHCHD10 variant for motor neuronopathy.
The association of CHCHD10 mutations in motor neuron disorder resembling ALS is further illustrated by the c.197G>T (p.Gly66Val) variant, which was originally described in a Finnish familial ALS patient with slowly ascending progressive motor neuronopathy. This variant was later shown to cause a lower motor neuron phenotype without upper motor neuron or cognitive involvement, as it was identified in 75 Finnish carriers with hereditary late onset spinal motor neuronopathy, Charcot-Marie-Tooth disease type 2, or both. 6, [31] [32] [33] Overall, there is evidence that some variants in CHCHD10 are associated with motor neuron degeneration, particularly in combination with clinical features that suggest mitochondrial dysfunction, such as myopathy or hearing loss. In the case of pure ALS, however, our results indicate that most rare genetic variants in CHCHD10 are detected in both cases and controls at similar frequencies. Thus, we find little evidence that CHCHD10 variants are a prevalent cause of pure ALS as has previously been suggested and do not support routine diagnostic or predictive testing for CHCHD10 variants in pure ALS. 5 Our study underlines the importance of gaining robust genetic and functional evidence to establish pathogenicity before advocating gene testing in a clinical setting.
